文献速递淋巴瘤

弥漫性大B细胞淋巴瘤中MYC与BCL2的遗传学分析决定起源细胞亚型特异性临床影响

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.
PubMed 文献 · Blood · 2017-03-28

研究对347例在不列颠哥伦比亚癌症机构接受R-CHOP治疗的初发弥漫性大B细胞淋巴瘤(DLBCL)病例,采用二代测序和高分辨率SNP阵列分析MYC与BCL2遗传学改变,并以Lymph2Cx数字基因表达谱判定起源细胞(COO)亚型。结果显示MYC/BCL2遗传学改变的发生率及临床意义在很大程度上取决于COO亚型,BCL2基因扩增/获得在活化B细胞样亚型中与不良结局显著相关,BCL2易位在生发中心B细胞亚型中与不良结局显著相关。

要点

  • BCL2扩增/获得在活化B细胞样亚型中与不良结局显著相关。
  • BCL2易位在生发中心B细胞亚型中与不良结局显著相关。
  • BCL2遗传学改变联合IPI可在各COO亚型内识别预后显著更差的组。

核心结论

  • 高分辨率基因组检测基于BCL2遗传学状态可在每个COO亚型内识别预后极差的组。
  • 作者认为基于BCL2遗传学改变的COO亚型特异性生物标志物可用于接受免疫化疗的DLBCL患者的风险分层。

研究设计与样本

  • 研究纳入347例初发DLBCL病例,均在不列颠哥伦比亚癌症机构接受R-CHOP(利妥昔单抗、环磷酰胺、多柔比星、长春新碱和泼尼松)治疗。
  • 采用二代测序和高分辨率SNP阵列分析MYC与BCL2遗传学改变。
  • COO亚型由Lymph2Cx数字基因表达谱判定。

主要发现

  • MYC/BCL2遗传学改变的发生率及其临床意义在很大程度上取决于COO亚型。
  • BCL2扩增/获得在活化B细胞样亚型中与不良结局显著相关。
  • BCL2易位在生发中心B细胞亚型中与不良结局显著相关。
  • 上述两项预后意义均独立于MYC/BCL2双表达和国际预后指数(IPI)。
  • BCL2遗传学改变联合IPI可在各COO亚型内识别预后显著更差的组。

临床怎么用

  • 原文结论提示基于BCL2遗传学改变的COO亚型特异性生物标志物可用于接受免疫化疗的DLBCL患者的风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical significance of MYC and BCL2 genetic alterations in diffuse large B-cell lymphoma (DLBCL), apart from translocations, has not been comprehensively investigated using high-resolution genetic assays. In this study, we profiled MYC and BCL2 genetic alterations using next-generation sequencing and high-resolution SNP array in 347 de novo DLBCL cases treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) at the British Columbia Cancer Agency. Cell-of-origin (COO) subtype was determined by Lymph2Cx digital gene expression profiling. We showed that the incidence of MYC/BCL2 genetic alterations and their clinical significance were largely dependent on COO subtypes. It is noteworthy that the presence of BCL2 gain/amplification is significantly associated with poor outcome in activated B-cell-like and BCL2 translocation with poor outcome in germinal center B-cell subtypes, respectively. Both have prognostic significance independent of MYC/BCL2 dual expression and the International Prognostic Index (IPI). Furthermore, the combination of BCL2 genetic alterations with IPI identifies markedly worse prognostic groups within individual COO subtypes. Thus, high-resolution genomic assays identify extremely poor prognostic groups within each COO subtype on the basis of BCL2 genetic status in this large, uniformly R-CHOP-treated population-based cohort of DLBCL. These results suggest COO subtype-specific biomarkers based on BCL2 genetic alterations can be used to risk-stratify patients with DLBCL treated with immunochemotherapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Ennishi D, Mottok A, Ben-Neriah S, et al. Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact. Blood. 2017. PMID: 28351934. doi:10.1182/blood-2016-11-747022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。